-
-
-
-
-
-
-
Shire Plc (SHPG) Reports Publication in JAMA of Complete Results of Phase 3 HELP Study Evaluating Lanadelumab
-
-
-
-
-
-
-
3rd Quarter Results
-
-
-
-
-
-
-
Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan
-
-
-
-
-
-
-
SHIRE ANNOUNCES THE PRICING TERMS AND INCREASE IN THE MAXIMUM TENDER AMOUNT OF THE PREVIOUSLY ANNOUNCED CASH TENDER OFFERS FOR CERTAIN OUTSTANDING NOTES
-
-
-
-
-
-
-
SHIRE ANNOUNCES CASH TENDER OFFERS FOR UP TO $2,250,000,000 OUTSTANDING PRINCIPAL AMOUNT OF NOTES
-
-
-
-
-
-
-
Shire (SHPG) option implied volatility elevated into Takeda reaches agreement to acquire for $62B in cash and stock
-
-
-
-
-
-
-
UPDATE: Takeda Offer for Shire (SHPG) is Insufficient - BTIG
-
1,155,369 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

